Revvity (NYSE:RVTY) FY Conference Transcript

Revvity (NYSE:RVTY) FY Conference Summary Company Overview - Revvity has undergone significant transformation over the past decade, evolving from a company with equal focus on analytical, life sciences, and diagnostics to a balanced portfolio of approximately $3 billion, split evenly between life sciences and diagnostics [2][4] - The life sciences business has expanded into large molecule capabilities, while diagnostics has diversified beyond reproductive health into autoimmune, allergy, and emerging diseases [3] Financial Performance - Revvity's revenue is approximately $3 billion, with 85% of the portfolio being recurring revenue [4] - The life sciences segment generates about $1.5 billion, with 85% from innovative reagents and instrumentation, and 15% from software [5] - The diagnostics segment also contributes around $1.5 billion, with 60% from immunodiagnostics and 40% from reproductive health [6] Growth Drivers - Revvity identifies four key growth pillars: 1. Software Business: Launching new products like Xynthetica, BioDesign, and Signals LabGistics, which are expected to enhance drug discovery and lab management [8][9][10] 2. Immunodiagnostics: Targeting a market share increase from 20% to 40% in the U.S. [11] 3. GMP Innovation: Building capabilities in Good Manufacturing Practices, with expectations for significant growth in the coming years [11][41] 4. Strategic Partnerships: Collaborations with companies like Sanofi and Genomics England to enhance service offerings [10] Market Outlook - Revvity anticipates organic growth of 2%-3% for 2026, with expectations of low single-digit growth in life sciences solutions and mid-single-digit growth in reproductive health [30][35] - The company does not expect a market recovery in pharma and biotech for 2026, but sees potential for growth in other areas [33] Operational Excellence - Revvity has improved free cash flow conversion to approximately 90% from a historical 70% [12] - The company plans for a 100 basis point margin expansion in 2026, with further expansion expected in 2027 due to cost benefits [13][68] AI and Drug Development - Revvity views AI as a net tailwind for both its reagents and software businesses, facilitating drug discovery and creating a validation bottleneck that will increase demand for wet lab services [20][26] - The company is positioned to leverage AI through its software offerings, creating a marketplace for AI models that integrates with existing lab research [21][25] Competitive Landscape - Revvity maintains a competitive advantage through best-in-class customer service, rapid delivery of reagents, and a strong innovation pipeline [44][45] - The company is monitoring competitive disruptions from industry transactions, such as the Waters BD transaction, but believes its moat remains strong [44] Challenges and Risks - The company has adopted a more prudent approach to growth assumptions in the Chinese market due to regulatory changes [58] - Potential tariff impacts on diagnostics manufacturing in Europe are being monitored, with plans to mitigate exposure [63] Conclusion - Revvity is optimistic about its growth trajectory, driven by innovation, strategic partnerships, and operational improvements, while navigating challenges in the pharma and biotech markets [16][70]